Biomedical Occupation or Discipline – Page 11

Major Clinical Trial Failures of 2024: Setbacks in Neuroscience and Beyond

6 months ago talkbio0Tagged Alzheimer 's disease, Amyotrophic Lateral Sclerosis, Clinical Trials, Drug Development, Duchenne, Neoplasms, Neuroscience discipline, Schizophrenia

Clinical trials, drug development, neuroscience, ALS, Alzheimer’s disease, schizophrenia, Duchenne muscular dystrophy, oncology

Biotech M&A Heats Up: Cosette’s $430M Mayne Pharma Acquisition and Industry-Wide Stock Buybacks

6 months ago talkbio0Tagged Acquisitions, biotech, Dermatology field, Lung consolidation, Market, pharmaceutical mergers, stock repurchase programs, women 's health

Biotech acquisitions, pharmaceutical mergers, stock repurchase programs, women’s health, dermatology, market consolidation

Incyte and Genesis Therapeutics Forge $620M AI-Driven Drug Discovery Partnership

6 months ago talkbio0Tagged Artificial Intelligence, Drug Discovery, Gemini of Coiled Bodies, Immunology, Neoplasms, small molecule therapeutics, strategic collaboration

Artificial intelligence, drug discovery, small molecule therapeutics, GEMS platform, oncology, immunology, strategic collaboration

RFK Jr. Backtracks on Vaccine Pledge, Announces Review of Childhood Immunization Schedule

6 months ago talkbio0Tagged CHARGE Syndrome, childhood vaccine schedule, Confirmation, Disease Outbreaks, measles, public health medicine (field), Robert F. Kennedy, Secretary, Senate

Robert F. Kennedy Jr., HHS Secretary, childhood vaccine schedule, review, controversy, public health, measles outbreak, Senate confirmation

Major Budget Cuts and Layoffs Hit US Health Agencies: Impacts on CDC, NIH, and Public Health

6 months ago talkbio0Tagged Administration occupational activities, Centers for Disease Control and Prevention (U.S.), healthcare budget, layoffs, Medical Research activity, NIH Mouse, public health medicine (field), Transplant Registry Unified Management Program

healthcare budget cuts, CDC layoffs, NIH funding reduction, public health impact, Trump administration, federal workforce reduction, medical research funding

AI-Guided Cardiac Ablation Outperforms Standard Treatment for Persistent Atrial Fibrillation

6 months ago talkbio0Tagged Artificial Intelligence, Atrial Fibrillation, Cardiac ablation, Electrophysiology (science), Medical service, Pulmonary veins, TAILORED-AF

Volta Medical, artificial intelligence, cardiac ablation, atrial fibrillation, TAILORED-AF trial, pulmonary vein isolation, electrophysiology

Biogen and Stoke Therapeutics Partner on Promising Dravet Syndrome Treatment

6 months ago talkbio0Tagged Antisense, Biogen, Drug Development, Epilepsy, Infantile Severe Myoclonic Epilepsy, Infrequent, Oligonucleotides, pharmaceutical partnership, Stoke, Zorevunersen

Biogen, Stoke Therapeutics, zorevunersen, Dravet syndrome, antisense oligonucleotide, rare epilepsy, drug development, pharmaceutical partnership

Mass Layoffs at HHS: Trump Administration Cuts Thousands of Probationary Workers

6 months ago talkbio0Tagged Administration occupational activities, Centers for Disease Control and Prevention (U.S.), HHS layoffs, NIH Mouse, public health medicine (field), Transplant Registry Unified Management Program, United States Food and Drug Administration, Workers

HHS layoffs, probationary employees, Trump administration, CDC, NIH, FDA, federal workforce reduction, public health impact

Trump Establishes Make America Healthy Again Commission to Combat Childhood Chronic Diseases

6 months ago talkbio0Tagged CHARGE Syndrome, Chronic disease, Commission, disease prevention, MAHA, public health medicine (field), Robert F. Kennedy Jr., Secretary

MAHA Commission, Robert F. Kennedy Jr., childhood chronic diseases, HHS Secretary, Executive Order, public health, chronic illness, disease prevention

Bambusa Therapeutics Secures $90M Series A Funding to Advance Bispecific Antibodies for I&I Disorders

6 months ago talkbio0Tagged Antibodies, Bispecific, Bambusa Therapeutics, Capital Management, Funding, Immunology, Inflammation, Rheumatoid Arthritis, Series

Bambusa Therapeutics, bispecific antibodies, immunology, inflammation, Series A funding, RA Capital Management, I&I disorders